Search

MediciNova Inc

Cerrado

SectorSanidad

1.54 1.32

Resumen

Variación precio

24h

Actual

Mínimo

1.45

Máximo

1.56

Métricas clave

By Trading Economics

Ingresos

-4.9B

-4.9B

Ventas

271K

458K

BPA

-0.05

Margen de beneficios

-1,068,366.946

Empleados

6

EBITDA

5.1K

-2.5M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+422.88% upside

Dividendos

By Acuity

Próximas Ganancias

10 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

65M

Apertura anterior

0.22

Cierre anterior

1.54

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

150 / 340 Clasificación en Healthcare

MediciNova Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 ago 2026, 20:02 UTC

MediciNova Inc shares are higher today, continuing a strong upward trend since Friday's close. The stock remains near the upper end of its one-month range.

21 ago 2026, 19:56 UTC

MediciNova Inc's shares are higher today, continuing a positive trend. The stock is trading above its 20-day moving average amid gains in the cryptocurrency sector.

20 ago 2026, 19:16 UTC

MediciNova Inc. shares are lower today, having previously declined significantly before recovering. The price remains above its 20-day moving average.

18 ago 2026, 19:56 UTC

MediciNova Inc shares are higher, reflecting positive market momentum. The stock remains above its 20-day moving average and near the upper end of its one-month range.

17 ago 2026, 19:56 UTC

News

MediciNova shares are higher as the company reported earnings of -$0.05 per share, surpassing estimates and generating $0.46 million in revenue.

13 ago 2026, 19:26 UTC

MediciNova Inc shares are lower amid broader market pressure from rising jobless claims and stabilizing inflation indicators. The stock trades near its one-month range low.

12 ago 2026, 19:56 UTC

MediciNova Inc. shares are trading roughly flat with no specific news identified, remaining near the lower end of their one-month trading range.

11 ago 2026, 20:06 UTC

MediciNova Inc. shares are roughly flat, showing little movement since Monday's close and positioned near the lower end of their one-month trading range.

10 ago 2026, 19:46 UTC

MediciNova Inc shares are lower today, continuing a downward trend since Friday. Broader market sentiment is affected by recent U.S. employment data.

7 ago 2026, 19:46 UTC

MediciNova Inc. shares are higher today, recovering from earlier losses. The stock is trading around the middle of its one-month range.

6 ago 2026, 20:13 UTC

MediciNova Inc shares are higher in after-market trading, reflecting strength since Thursday's close amid rising U.S. Treasury yields and a hawkish Fed outlook.

4 ago 2026, 19:36 UTC

MediciNova Inc. shares are trading roughly flat amid broader market reactions to a decline in U.S. core factory orders and ongoing strength in AI sectors.

3 ago 2026, 20:06 UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

31 jul 2026, 19:56 UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

30 jul 2026, 20:51 UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

29 jul 2026, 20:09 UTC

MediciNova Inc shares are lower today, continuing a decline since Tuesday's close, and remain near their opening low amid broader market trends.

28 jul 2026, 18:46 UTC

MediciNova Inc. shares are trading higher today, remaining above Monday's close despite settling back from earlier gains during the session.

27 jul 2026, 19:06 UTC

MediciNova Inc. shares are lower today, reflecting broader market trends amid a significant decline in crude oil prices following eased geopolitical tensions.

24 jul 2026, 23:02 UTC

MediciNova Inc shares increased in after-hours trading, reflecting strong performance since Friday's close, despite mixed market sentiment and no specific company news.

23 jul 2026, 20:06 UTC

MediciNova Inc. shares are lower today, continuing a six-session decline amid routine volatility and remaining significantly below the 20-day moving average.

21 jul 2026, 19:21 UTC

MediciNova Inc. shares are lower amid no specific news, continuing a trend below the 20-day moving average over the past three sessions.

Comparación entre iguales

Cambio de precio

MediciNova Inc previsión

Precio Objetivo

By TipRanks

422.88% repunte

Estimación a 12 Meses

Media 8 USD  422.88%

Máximo 10 USD

Mínimo 6 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para MediciNova Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

150 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
help-icon Live chat